NASDAQ:HCM - HUTCHMED Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $47.67
  • Forecasted Upside: 35.49 %
  • Number of Analysts: 4
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 3 Buy Ratings
  • 0 Strong Buy Ratings
$35.18
▲ +2.02 (6.09%)

This chart shows the closing price for HCM by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New HUTCHMED Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for HCM and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for HCM

Analyst Price Target is $47.67
▲ +35.49% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for HUTCHMED in the last 3 months. The average price target is $47.67, with a high forecast of $52.00 and a low forecast of $45.00. The average price target represents a 35.49% upside from the last price of $35.18.

This chart shows the closing price for HCM for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 4 investment analysts is to buy stock in HUTCHMED. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
6/5/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
9/3/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
12/2/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/2/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/31/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/29/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
10/28/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
11/27/2021

Latest Recommendations

  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
9/22/2021The Goldman Sachs GroupDowngradeBuy ➝ Neutral$46.00High
8/3/2021Jefferies Financial GroupInitiated CoverageBuy$52.00Low
7/13/2021Cantor FitzgeraldBoost Price TargetOverweight$40.00 ➝ $45.00Low
2/16/2021MizuhoInitiated CoverageBuyLow
10/2/2020Deutsche Bank AktiengesellschaftInitiated CoverageBuy$40.00Medium
3/12/2020Cantor FitzgeraldInitiated CoverageOverweightHigh
2/20/2020The Goldman Sachs GroupInitiated CoverageBuyLow
11/19/2019CLSAInitiated CoverageBuyLow
10/23/2019Bank of AmericaInitiated CoverageBuy$35.00 ➝ $29.00High
7/5/2019MacquarieInitiated CoverageOutperform ➝ OutperformLow
3/27/2019HSBCInitiated CoverageBuyLow
3/4/2019Deutsche Bank AktiengesellschaftInitiated CoverageBuy$26.82Low
10/16/2017Canaccord GenuityBoost Price TargetBuy$38.00N/A
7/31/2017Canaccord GenuitySet Price TargetBuy$30.00Low
6/6/2017Canaccord GenuitySet Price TargetBuy$30.00Low
5/18/2017Canaccord GenuitySet Price TargetBuy$30.00Low
4/4/2017Stifel NicolausBoost Price TargetBuy$22.00 ➝ $26.00Medium
4/1/2017Canaccord GenuitySet Price TargetBuy$30.00Low
3/14/2017Stifel NicolausReiterated RatingBuy ➝ Buy$20.00 ➝ $22.00Low
3/11/2017Canaccord GenuitySet Price TargetBuy$20.00High
3/3/2017Canaccord GenuitySet Price TargetBuy$20.00N/A
2/14/2017Canaccord GenuitySet Price TargetBuy$20.00N/A
1/27/2017Canaccord GenuitySet Price TargetBuy$20.00N/A
12/6/2016Canaccord GenuityReiterated RatingBuy$20.00N/A
(Data available from 11/28/2016 forward)

News Sentiment Rating

0.00 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/2/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/1/2021
  • 0 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 2 very negative mentions
7/1/2021
  • 5 very positive mentions
  • 24 positive mentions
  • 3 negative mentions
  • 3 very negative mentions
7/31/2021
  • 2 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
8/30/2021
  • 3 very positive mentions
  • 9 positive mentions
  • 1 negative mentions
  • 2 very negative mentions
9/29/2021
  • 2 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/29/2021
  • 0 very positive mentions
  • 10 positive mentions
  • 2 negative mentions
  • 1 very negative mentions
11/28/2021

Current Sentiment

  • 0 very positive mentions
  • 10 positive mentions
  • 2 negative mentions
  • 1 very negative mentions
HUTCHMED logo
HUTCHMED (China) Limited discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases worldwide. It operates in two segments, Oncology/Immunology and Other Ventures. It manufactures, distributes, markets, and sells prescription and over-the-counter pharmaceutical, and consumer health products. The company is developing Savolitinib, an inhibitor for non-small cell lung cancer (NSCLC), papillary and clear cell renal cell carcinoma, colorectal cancer (CRC), and gastric cancer (GC); and Fruquintinib, an inhibitor for CRC, breast cancer, GC, endometrial cancer (EMC), NSCLC, hepatocellular carcinoma, and gastrointestinal and solid tumors. It also develops Surufatinib, an inhibitor for neuroendocrine tumors (NET), pancreatic NET, non-pancreatic NET, biliary tract cancer, sarcoma, neuroendocrine neoplasm, esophageal cancer, small cell lung cancer, GC, thyroid cancer, EMC, NSCLC, and solid tumors; HMPL-523, an inhibitor for indolent non-Hodgkin's lymphoma (NHL), B-cell malignancies, and immune thrombocytopenic purpura; and HMPL-689 for indolent non-Hodgkin's, follicular, marginal zone, mantle cell, diffuse large B cell, chronic lymphocytic leukemia/small lymphocytic, and Hodgkin's lymphoma. The company is developing HMPL-453, an inhibitor for intrahepatic cholangiocarcinoma; HMPL-306, an inhibitor for hematological malignancies, gliomas, and solid tumors; HMPL-295 for solid tumors; and HMPL-813 and HMPL-309 EGFR inhibitors. HUTCHMED (China) Limited has collaboration agreements with AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, BeiGene, Inmagene Biopharmaceuticals Co. Ltd., Innovent Biologics (Suzhou) Co., Inc., Genor Biopharma Co. Ltd., and Shanghai Junshi Biosciences Co. Ltd. The company was formerly known as Hutchison China MediTech Limited and changed its name to HUTCHMED (China) Limited in May 2021. HUTCHMED (China) Limited was incorporated in 2000 and is headquartered in Central, Hong Kong.
Read More

Today's Range

Now: $35.18
Low: $34.03
High: $35.75

50 Day Range

MA: $32.78
Low: $29.42
High: $38.18

52 Week Range

Now: $35.18
Low: $23.67
High: $43.94

Volume

239,443 shs

Average Volume

272,473 shs

Market Capitalization

$6.08 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.97

Frequently Asked Questions

What sell-side analysts currently cover shares of HUTCHMED?

The following Wall Street sell-side analysts have issued research reports on HUTCHMED in the last twelve months: Cantor Fitzgerald, Jefferies Financial Group Inc., Mizuho, The Goldman Sachs Group, Inc., and Zacks Investment Research.
View the latest analyst ratings for HCM.

What is the current price target for HUTCHMED?

3 Wall Street analysts have set twelve-month price targets for HUTCHMED in the last year. Their average twelve-month price target is $47.67, suggesting a possible upside of 35.5%. Jefferies Financial Group Inc. has the highest price target set, predicting HCM will reach $52.00 in the next twelve months. Cantor Fitzgerald has the lowest price target set, forecasting a price of $45.00 for HUTCHMED in the next year.
View the latest price targets for HCM.

What is the current consensus analyst rating for HUTCHMED?

HUTCHMED currently has 1 hold rating and 3 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe HCM will outperform the market and that investors should add to their positions of HUTCHMED.
View the latest ratings for HCM.

How do I contact HUTCHMED's investor relations team?

HUTCHMED's physical mailing address is 48TH FLOOR CHEUNG KONG CENTER 2 QUEEN`S ROAD CENTRAL, HONG KONG K3, . The company's listed phone number is 852-2121-3888 and its investor relations email address is [email protected] The official website for HUTCHMED is www.chi-med.com.